Skip to main content
main-content

The independent medical news service

10-10-2019 | Oncology | Highlight | Article

PROfound paves the way for precision medicine in mCRPC

Treatment with the PARP inhibitor olaparib improves the outcomes of men with metastatic castration-resistant prostate cancer harboring deleterious mutations in homologous recombination repair genes, show trial results.

08-10-2019 | Oncology | News | Article

HRQoL data bolster positive survival findings from TITAN study

Adding apalutamide to androgen deprivation therapy does not result in increased levels of pain or fatigue, relative to placebo, nor does it negatively impact overall health-related quality of life, shows an analysis of data from the TITAN study.

08-10-2019 | Oncology | News | Article

Ultra-hypofractionated SBRT has low acute toxicity in localized prostate cancer

Ultra-hypofractionated stereotactic body radiotherapy does not increase the risk for acute toxicity over standard of care radiotherapy in men with localized prostate cancer, according to a phase III trial.

30-09-2019 | Oncology | News | Article

CARD results support cabazitaxel use in mCRPC

Cabazitaxel could be an option for men with metastatic castration-resistant prostate cancer who have progressed after treatment with docetaxel and an androgen signaling-targeted agent, suggest trial findings.

28-09-2019 | Oncology | News | Article

Apalutamide may improve OS in men with nonmetastatic CRPC

An interim analysis from the SPARTAN trial points to an overall survival benefit with the use of apalutamide alongside androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer.

28-09-2019 | Oncology | News | Article

STAMPEDE shows docetaxel benefit regardless of metastatic burden

Men with metastatic hormone-naïve prostate cancer have improved outcomes with the addition of docetaxel to androgen deprivation therapy irrespective of whether they have high or low burden of disease, indicates an analysis of the STAMPEDE trial.

Image Credits